- Home
- PYN vs NRXP Comparison
PYN vs NRXP Comparison
Compare PYN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- NRXP
- Stock Information
- Founded
- PYN 2002
- NRXP 2015
- Country
- PYN United States
- NRXP United States
- Employees
- PYN N/A
- NRXP N/A
- Industry
- PYN Investment Managers
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- NRXP Health Care
- Exchange
- PYN Nasdaq
- NRXP Nasdaq
- Market Cap
- PYN 30.1M
- NRXP 32.6M
- IPO Year
- PYN N/A
- NRXP N/A
- Fundamental
- Price
- PYN $5.33
- NRXP $3.39
- Analyst Decision
- PYN
- NRXP Strong Buy
- Analyst Count
- PYN 0
- NRXP 4
- Target Price
- PYN N/A
- NRXP $28.50
- AVG Volume (30 Days)
- PYN 19.9K
- NRXP 267.4K
- Earning Date
- PYN 01-01-0001
- NRXP 08-13-2025
- Dividend Yield
- PYN 5.07%
- NRXP N/A
- EPS Growth
- PYN N/A
- NRXP N/A
- EPS
- PYN N/A
- NRXP N/A
- Revenue
- PYN N/A
- NRXP N/A
- Revenue This Year
- PYN N/A
- NRXP N/A
- Revenue Next Year
- PYN N/A
- NRXP N/A
- P/E Ratio
- PYN N/A
- NRXP N/A
- Revenue Growth
- PYN N/A
- NRXP N/A
- 52 Week Low
- PYN $4.84
- NRXP $1.10
- 52 Week High
- PYN $6.60
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- PYN 54.42
- NRXP 60.08
- Support Level
- PYN $5.25
- NRXP $2.90
- Resistance Level
- PYN $6.13
- NRXP $3.53
- Average True Range (ATR)
- PYN 0.11
- NRXP 0.19
- MACD
- PYN 0.01
- NRXP -0.03
- Stochastic Oscillator
- PYN 11.29
- NRXP 84.13
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.